Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: Final report

Vaccine

Volumn 26, Issue 51, 2008, Pages 6587-6591

  But, David Yiu Kuen ^a   Lai, Ching Lung ^a   Lim, Wei Ling ^b   Fung, James ^a   Wong, Danny Ka Ho ^a   Yuen, Man Fung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b Department of Health ^*  (Hong Kong)

Author keywords

HBV infection; Immunogenicity; Vaccination

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; VACCINATION;

CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; INFANT; MALE; PROSPECTIVE STUDIES; VACCINES, DNA;

EID: 58149105757     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.09.034     Document Type: Article

References (18)

1. Lai C.L., and Yuen M.F. The natural history of chronic hepatitis B. J Viral Hepat 14 Suppl. 1 (2007) 6-10
2. Beasley R.P., Trepo C., Stevens C.E., and Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 105 (1977) 94-98
3. Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Wu T.C., Kong M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children: Taiwan Childhood Hepatoma Study Group. N Engl J Med 336 (1997) 1855-1859
4. Lin H.H., Wang L.Y., Hu C.T., Huang S.C., Huang L.C., Lin S.S., et al. Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan. J Med Virol 69 (2003) 471-474
5. Jacob J.T., and Cooksley G. Hepatitis B vaccine boosters: is there a clinical need in high endemicity populations?. J Gastroenterol Hepatol 20 (2005) 5-10
6. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991;40(RR-13):1-19.
7. National Advisory Committee on Immunization. Revised guideline for booster vaccination against hepatitis B. Can Commun Dis Rep 18 16 (1992) 121-122
8. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000;355:561-5.
9. van der Sande M.A., Mendy M., Waight P., Doherty C., McConkey S.J., Hall A.J., et al. Similar long-term vaccine efficacy of two versus three doses of HBV vaccine in early life. Vaccine 25 (2007) 1509-1512
10. Whittle H.C., Maine N., Pilkington J., Mendy M., Fortuin M., Bunn J., et al. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet 345 (1995) 1089-1092
11. Lai C.L., Wong B.C.Y., Yeoh E.K., Lim W.L., Chang W.K., and Lin H.J. Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: immunogenicity and anamnestic responses. Hepatology 18 (1993) 763-767
12. Yuen M.F., Lim W.L., Cheng C.C., Lam S.K., and Lai C.L. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. Hepatology 29 (1999) 924-927
13. Yuen M.F., Li W.L., Chan A.O., Wong D.K., Sum S.S., and Lai C.L. 18-Year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clin Gastroenterol Hepatol 2 (2004) 941-945
14. Wilson J.N., and Nokes D.J. Do we need 3 doses of hepatitis B vaccine?. Vaccine 17 (1999) 2667-2673
15. Theppisai U., Thanuntaseth C., Chiewsilp P., and Siripoonya P. Long-term immunoprophylaxis of hepatitis B surface antigen positive mothers using plasma derived vaccine. Asia Oceania J Obstet Gynaecol 15 (1989) 111-115
16. Wistrom J., Ahlm C., Lundberg S., Settergren B., and Tarnvik A. Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose. Vaccine 17 (1999) 2162-2165
17. Lu C.Y., Chiang B.L., Chi W.K., Chang M.H., Ni Y.H., Hsu H.M., et al. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 40 (2004) 1415-1420
18. Young B.W.Y., Lee S.S., Lim W.L., and Yeoh E.K. The long-term efficacy of plasma-derived hepatitis B vaccine in babies born to carrier mothers. J Viral Hepat 10 (2003) 23-30